If you have typed "how to get retatrutide in Australia" into Google this year, you have probably hit a wall of vague answers. August 2026 changed part of that picture: Eli Lilly formally opened a pre-approval expanded access programme for retatrutide in the United States, after months of pressure from doctors. That is real, documented news — but it does not automatically translate into an Australian prescription. Here is the honest access map as it stands today, including the single clause in TGA policy that decides most of these cases.

What actually changed overseas in August 2026

On 3 August 2026, Lilly confirmed it would let a defined group of patients apply for access to retatrutide ahead of FDA approval. The programme followed scrutiny of an earlier one-off compassionate-use case, and it is registered on ClinicalTrials.gov as a pre-approval expanded access record (NCT07629401) rather than as a conventional interventional trial.

The published eligibility criteria are narrow. A patient must have refractory obesity — BMI of 35 or above despite adherence to, and tolerance of, the highest available dose of an existing chronic weight-management therapy — plus two or more serious or life-threatening obesity-related complications currently being treated to standard of care. They must also be unable to join an ongoing trial of retatrutide or a comparable investigational medicine, and must have discussed every standard option, including bariatric surgery, with their clinician.

That is not a back door for someone who wants a faster result than Wegovy gave them. Commentary in the clinical press has noted, fairly, that most people asking about retatrutide would not clear that bar. Lilly still says it plans to file its application with the FDA in the first quarter of 2027, with TGA submission following its own timetable.

How to get retatrutide in Australia: the three doors

For an Australian in 2026 there are three theoretical routes, and only one of them is genuinely open to ordinary applicants.

Door 1 — a clinical trial site

This remains the only conventional way an Australian receives retatrutide with a clinician monitoring them and a supply chain behind it. Australia has been a meaningful contributor to the TRIUMPH programme, with trial listings showing sites across Canberra, Sydney, Brisbane, Adelaide, Melbourne, Geelong and Perth suburbs. The catch is timing: most numbered TRIUMPH obesity trials have already closed enrolment, and newer protocols such as TRIUMPH-9 (NCT07357415) were still listed as recruiting mid-year with site lists that change without notice. If this route matters to you, the registry listing — not a blog post — is the live source. Our clinical trials page explains what the programme is testing and why the arms differ.

Door 2 — the Special Access Scheme, and the clause nobody quotes

Australia's equivalent of expanded access is the TGA's Special Access Scheme. For an unapproved medicine like retatrutide, a doctor would apply under SAS Category B, which requires TGA approval before any supply occurs; the TGA issues an approval number in a letter to the requesting practitioner.

Here is the part that decides the outcome. TGA guidance for sponsors states plainly that a sponsor is not obliged to supply an unapproved therapeutic good, and may refuse even when a prescriber produces evidence of TGA approval. In other words, an SAS-B approval is permission, not product. The rate-limiting step for retatrutide in Australia is not paperwork at the regulator — it is whether the manufacturer is willing to ship a Phase 3 asset outside its own trial and access programmes. A TGA approval letter cannot compel that.

Door 3 — waiting for registration

The ordinary route. Retatrutide is investigational and not TGA-approved, and Lilly has signalled regulatory filings from 2027 onward. Until an ARTG entry exists, no Australian pharmacy dispenses it and no PBS listing can apply. We track that process on our Australia page.

Why this matters more here than the headlines suggest

Roughly 66.8% of Australian adults live with overweight or obesity, so the pool of people with a genuine clinical case for a stronger agent is not small. But Australia already has TGA-approved options — semaglutide (Ozempic, Wegovy), which acts on one receptor, and tirzepatide (Mounjaro, Zepbound), which acts on two. Retatrutide adds a third target, glucagon. Under SAS logic, the existence of approved alternatives makes the clinical justification for an unapproved medicine harder, not easier, and that is before the supply question is reached.

The efficacy signal is why people keep asking. TRIUMPH-1 reported up to about 28.3% average body weight reduction at the 12 mg dose over 80 weeks, with 45.3% of participants losing 30% or more. Those are trial figures under trial conditions — read them alongside the tolerability picture on our safety page, and the mechanism explainer at what is retatrutide.

One caveat worth stating plainly: the reporting and registry material available today describes the expanded access programme in a US regulatory frame. We found no confirmation of an Australian arm, and we are not assuming one exists.

Want the next confirmed Australian milestone — filing, ARTG entry, or a new recruiting site — in your inbox? Join the free updates list.

FAQ

How do you get retatrutide in Australia right now?

The only conventional route is enrolment in a clinical trial at an Australian site, and most TRIUMPH obesity trials have closed recruitment. Retatrutide is not TGA-approved, so no pharmacy can dispense it and no PBS subsidy exists.

Can an Australian doctor apply for retatrutide under the Special Access Scheme?

A doctor can lodge an SAS Category B application, which requires TGA approval before supply. However, TGA guidance states a sponsor is not obliged to supply an unapproved good even after approval, so willingness of the manufacturer — not the application — is usually the deciding factor.

Does Eli Lilly's expanded access programme cover Australia?

Lilly opened a pre-approval expanded access programme in August 2026 with strict criteria, registered on ClinicalTrials.gov as NCT07629401. The available reporting describes it in a US regulatory context, and we have seen no confirmation of an Australian arm.

When will retatrutide be approved in Australia?

Lilly has said it intends to file with the FDA in the first quarter of 2027, with other regulators on their own timelines. No TGA decision date has been announced, and any approval would follow a full ARTG registration process.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA. Talk to your GP or a qualified health professional about weight management options that are available and appropriate for you. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.